Jevtana

Prostate Cancer Treatment

Jevtana is used to treat metastatic castration-resistant prostate cancer. This is a type of prostate cancer that has spread to other areas of the body and no longer responds to medical or surgical treatments that lower testosterone levels.

This medication is specifically indicated for patients who meet the following criteria:

• The cancer has spread to other parts of the body (metastatic).
• The patient has previously been treated with a chemotherapy regimen that included docetaxel.
• It is used in combination with a corticosteroid medication, such as prednisone or prednisolone.

Jevtana belongs to a class of drugs known as microtubule inhibitors. It works by interfering with the ability of cancer cells to divide and grow, which may help slow the progression of the disease.

Mechanism of Action

Jevtana belongs to a group of medicines called taxanes. It works by targeting the internal framework of cells, specifically structures known as microtubules.

Microtubules are essential for cell division. In a healthy cycle, these structures constantly assemble and disassemble to help the cell split into two. Jevtana binds to these microtubules and prevents them from breaking down. This stabilization freezes the cell's internal machinery, making it impossible for the cell to complete the division process.

Because cancer cells divide much more rapidly than most normal cells, they are particularly sensitive to this interference. By preventing cell division, Jevtana helps to:

• Slow the growth of the tumor.
• Stop the spread of cancer cells to other parts of the body.
• Induce cell death in the targeted cancer cells.

Common Side Effects

Many people using Jevtana experience mild to moderate side effects. These may include:

• Nausea, vomiting, or stomach pain
• Diarrhea or constipation
• Feeling unusually tired or weak
• Thinning hair or hair loss
• Numbness, tingling, or burning sensations in the hands or feet
• Changes in the sense of taste
• Back pain or joint pain
• Shortness of breath or a cough

Serious Side Effects

Some side effects can be severe and require immediate medical attention. Contact a healthcare provider right away if you experience:

• Signs of infection: Fever, chills, sore throat, or other flu-like symptoms, which may indicate low white blood cell counts.
• Severe allergic reactions: Rash, hives, swelling of the face or throat, or difficulty breathing.
• Severe digestive issues: Intense diarrhea or signs of dehydration.
• Urinary problems: Blood in the urine or pain during urination.
• Lung problems: New or worsening cough or significant trouble breathing.
• Kidney issues: Changes in the amount or color of urine.

Boxed Warnings

Neutropenia: Jevtana can cause a severe decrease in white blood cells (neutropenia), which significantly increases the risk of serious or fatal infections. Healthcare providers monitor blood counts weekly during the first cycle and before each subsequent treatment. Treatment may be delayed or the dose reduced if counts are too low.

Hypersensitivity: Severe and sometimes fatal allergic reactions can occur, often within minutes of starting the infusion. Patients typically receive premedication with antihistamines, corticosteroids, and H2 antagonists to reduce this risk. Infusions must be stopped immediately if a severe reaction occurs.

Gastrointestinal Complications

Severe diarrhea and dehydration can occur during treatment. In some cases, Jevtana has been associated with serious gastrointestinal issues such as bleeding, holes in the stomach or intestine (perforation), and intestinal blockage (ileus). Patients experiencing severe abdominal pain or persistent diarrhea require immediate medical attention.

Kidney and Lung Health

There is a risk of kidney failure, which may be related to dehydration, low blood pressure, or infection. Additionally, some patients have developed interstitial lung disease or pneumonitis, which can cause cough and difficulty breathing. New or worsening respiratory symptoms should be reported to a healthcare provider immediately.

Contraindications

Jevtana should not be used in patients who have:

• A history of severe allergic reactions to cabazitaxel or other drugs containing polysorbate 80.
• A white blood cell count (neutrophils) of 1,500/mm3 or less.
• Severe liver impairment.

Use in Older Adults

Patients aged 65 and older may be more likely to experience certain side effects, including fatigue, weakness, infection, and dehydration, compared to younger patients. Close monitoring is especially important for this age group.

Pregnancy Risks

Jevtana is not indicated for use in women. Based on its mechanism of action and findings from animal studies, this medication can cause significant harm to a developing fetus if exposure occurs during pregnancy.

Contraception for Men

Because Jevtana can affect sperm and potentially cause birth defects, male patients with female partners who are able to become pregnant should follow these precautions:

• Use effective contraception (birth control) during treatment.
• Continue using effective contraception for 3 months after the final dose of Jevtana.

Breastfeeding

It is not known whether Jevtana passes into human breast milk. Due to the potential for serious adverse reactions in a nursing infant, breastfeeding is not recommended during treatment with this medication.

Fertility

Animal studies suggest that Jevtana may impair male fertility. Men who are concerned about their ability to father a child in the future should discuss these risks and potential options with their healthcare provider before starting treatment.

Dosage Forms

Jevtana is supplied as a kit for injection. This kit typically includes:

• A single-dose vial containing the active medication as a concentrated solution.
• A separate vial containing a diluent used to prepare the medication for administration.

The medication must be mixed and diluted by a healthcare provider before use. It is administered as an intravenous (IV) infusion, which means it is delivered directly into a vein.

FDA Approval and Indications

The U.S. Food and Drug Administration (FDA) approved Jevtana in June 2010. It is indicated for use in combination with prednisone to treat patients with metastatic castration-resistant prostate cancer who were previously treated with a docetaxel-containing regimen. In 2017, the FDA approved a lower dose (20 mg/m2 every three weeks) to provide an alternative for patients who may not tolerate the standard dose of 25 mg/m2.

Boxed Warnings

Jevtana includes a boxed warning regarding several serious safety risks:

• Neutropenia: This condition involves a severe drop in white blood cell counts, which can lead to life-threatening infections. Deaths related to infection have been reported. Patients must have frequent blood count monitoring during treatment.
• Hypersensitivity Reactions: Severe allergic reactions can occur, including low blood pressure and respiratory distress. Patients are usually given antihistamines and corticosteroids before treatment to minimize this risk.
• Gastrointestinal Complications: Severe diarrhea, dehydration, and gastrointestinal hemorrhage or perforation have occurred, some of which were fatal.

Jevtana is also contraindicated in patients with severe hepatic impairment or those with low baseline neutrophil counts.

Regulatory Status and Generics

Generic versions of cabazitaxel are FDA-approved and available. The medication is administered as an intravenous infusion by healthcare professionals in a clinical setting. There are no Risk Evaluation and Mitigation Strategy (REMS) programs currently required for this drug, but it must be administered under the supervision of a physician experienced in the use of cancer chemotherapeutic agents.

Cost and Coverage

The total cost of Jevtana treatment depends on several factors, including the setting where the medication is administered and the patient's insurance coverage. Because Jevtana is an intravenous injection given by a healthcare professional, it is usually covered under the medical benefit portion of insurance plans rather than a pharmacy benefit. For patients with Medicare, it is typically covered under Medicare Part B.

Generic Options

Generic versions of cabazitaxel are available. Generic medications typically cost less than brand-name drugs. Patients should consult their healthcare provider or insurance company to see if a generic version is a suitable and more affordable option for their treatment plan.

Financial Assistance

Financial assistance programs may be available through the drug manufacturer or third-party organizations to help reduce out-of-pocket costs for eligible patients. These programs often include co-pay cards or patient assistance for those who are uninsured or underinsured. Patients are encouraged to speak with a financial counselor at their treatment facility to explore these options.